Synektik (SNTP) Q4 2025 earnings summary

Executive summary

• Achieved 9% year-over-year growth in consolidated revenue to 681.3 mln PLN for the period ending 30 September 2025, with a 24% increase in EBITDA from continuing operations to 177.1 mln PLN and a 24% rise in total comprehensive income to 102.1 mln PLN.

• Strong performance in the medical equipment and IT segment, with recurring revenues up 60% year-over-year and a 29% increase in segment EBITDA.

• Radio-pharmaceuticals segment revenue grew 12% year-over-year, though EBITDA remained stable due to higher costs.

• Strategic decision to spin off the R&D and cardiomarker business into a new entity, Syn2bio SA, impacting segment reporting and financials.

Financial highlights

• Revenue: 681.3 mln PLN (up from 624.1 mln PLN year-over-year).

• Net profit: 102.2 mln PLN (up from 82.6 mln PLN year-over-year).

• EBITDA from continuing operations: 177.1 mln PLN (up from 143.1 mln PLN year-over-year).

• ROE increased to 46% from 43% year-over-year.

• Net cash from operating activities: 77.7 mln PLN (down from 89.6 mln PLN year-over-year).

Outlook and guidance

• Management expects continued growth in medical equipment, IT, and recurring revenues, supported by public healthcare investments and expansion in Central and Eastern Europe.

• Ongoing development in surgical robotics, new product launches, and expansion of radio-pharmaceuticals portfolio are key growth drivers.

• No financial forecasts for FY2025 were published.